NCT03636035 is a NA clinical trial of Tregocel® in Mild Knee Osteoarthritis, sponsored by Max Biocare Pty. Ltd..

Who is sponsoring NCT03636035?

NCT03636035 is sponsored by Max Biocare Pty. Ltd..

What drugs are being tested in NCT03636035?

Interventions in NCT03636035: Tregocel®.

What condition does NCT03636035 study?

NCT03636035 studies Mild Knee Osteoarthritis.

Is NCT03636035 still recruiting?

NCT03636035 is currently completed. Last updated 21 September 2022.

Last reviewed 2022-09-21 · How we verify

NCT03636035

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tregocel® as a Dietary Supplement in Mild Knee Osteoarthritis

Completed NA Last updated 21 September 2022

What this trial tests

NA trial testing Tregocel® in Mild Knee Osteoarthritis in 150 participants. Completed in 30 June 2020.

Timeline

1 January 2019

Primary endpoint
30 June 2020

30 June 2020

Quick facts

Lead sponsor	Max Biocare Pty. Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	150
Start date	1 January 2019
Primary completion	30 June 2020
Estimated completion	30 June 2020
Sites	1 location across Poland

Drugs / interventions tested

Tregocel®

Conditions studied

Mild Knee Osteoarthritis — all drugs for Mild Knee Osteoarthritis →

Sponsor

Max Biocare Pty. Ltd.

Who can join

40 and older, any sex, with Mild Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an assessment of the overall performance of participants with symptomatic mild knee OA taking Tregocel® as a dietary supplement in addition to standard of care treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prospective, Multicenter Evaluation of a Polyherbal Supplement alongside Standard-of-Care Treatment for Mild Knee Osteoarthritis.
Żęgota Z, Goździk J, Głogowska-Szeląg J. · · 2021 · cited 3× · PMID 34035964 · DOI 10.1155/2021/5589597
IMPROVED PHYSICAL FUNCTION WITH COMPLEMENTARY USE OF A DIETARY SUPPLEMENT FOR MILD KNEE OSTEOARTHRITIS: A SUBGROUP ANALYSIS.
Żęgota Z, Goździk J, Głogowska-Szeląg J. · · 2021 · PMID 34725289 · DOI 10.36740/wlek202109119

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03636035 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Max Biocare Pty. Ltd.
Last refreshed: 21 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03636035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing